P2, N=30, Completed, Coherus Oncology, Inc. | Active, not recruiting --> Completed | N=134 --> 30

P1, N=145, Completed, Coherus Oncology, Inc. | Active, not recruiting --> Completed | N=260 --> 145 | Trial completion date: Aug 2026 --> Jun 2025 | Trial primary completion date: Dec 2025 --> May 2025

P1, N=23, Terminated, Pfizer | N=103 --> 23 | Trial completion date: Jun 2026 --> Aug 2025 | Recruiting --> Terminated | Trial primary completion date: Jun 2026 --> Aug 2025; The Sponsor has decided to terminate the above referenced clinical study for business reasons. There were no safety concerns that led to this decision and there was no impact to participant safety.

P1, N=260, Active, not recruiting, Coherus Biosciences, Inc. | Recruiting --> Active, not recruiting

Here, we recapitulate the intricate mechanisms of IL-27, providing a comprehensive understanding of its immune-stimulating and immune-suppressing functions in the TME. This challenge is crucial for designing immunotherapies based on IL-27 in cancer.

Collectively, IL-27 is significantly induced by HBV in the liver, and its production is strongly associated with HBV persistence and CD8 T cell dysfunction. This highlights the immunosuppressive role of IL-27 in the liver microenvironment and suggests that IL-27 could serve as a potential therapeutic target for HBV infection.

P2, N=134, Active, not recruiting, Coherus Biosciences, Inc. | Trial completion date: May 2026 --> Jun 2025

In addition, IL-27 mRNA-LNPs served as an adjuvant that improved cytolytic CD8 + T cell responses and the therapeutic efficacy of mRNA-LNPs to drive anti-pathogen and anti-tumor immunity. These studies highlight the central role of IL-27 in mRNA-LNP induced CD8 + T cell responses and the ability of this cytokine to augment the functionality of the CD8 + T cell response for prophylactic or therapeutic immunization.

P2, N=72, Recruiting, Coherus Biosciences, Inc. | Not yet recruiting --> Recruiting

The increased circulating levels of anti-inflammatory cytokines IL-27 and IL-38 under PCOS conditions warrant further investigation. To the best of our knowledge, this is the first report on IL-38 levels in PCOS.

Finally, BI extended mouse survival in a chemoresistant model and significantly improved chemotherapy response in a chemo-sensitive model. In summary, we propose a new therapeutic strategy for the treatment of metastatic OvCa.

P2, N=72, Not yet recruiting, Coherus Biosciences, Inc.